2018 Irritable Bowel Syndrome Drug Development- Pipeline Analysis Report
Irritable bowel syndrome (IBS) is a chronic gastrointestinal and functional bowel disorder that affects around 10-15% of population during their lifetime. It causes abdominal pain, cramps, bloating, diarrhea or constipation. The drug market for the disease is estimated to be around $1.5 billion.
Over 50 companies and universities are focusing on developing treatment options for Irritable Bowel Syndrome.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Irritable Bowel Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Irritable Bowel Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Irritable Bowel Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 50 companies and universities are focusing on developing treatment options for Irritable Bowel Syndrome.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Irritable Bowel Syndrome pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Irritable Bowel Syndrome pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Irritable Bowel Syndrome pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 IRRITABLE BOWEL SYNDROME PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Irritable Bowel Syndrome Pipeline Snapshot
2.3 Irritable Bowel Syndrome Pipeline by Phase
2.4 Irritable Bowel Syndrome Pipeline by Company
2.5 Irritable Bowel Syndrome Pipeline by Mechanism of Action
3 IRRITABLE BOWEL SYNDROME- COMPANY WISE PIPELINE ANALYSIS
4D Pharma PLC
Alfa Wassermann SpA
Allergan
Aptevo Therapeutics Inc
Ardelyx Inc
Assembly Biosciences
Astellas Pharma Inc
Axim Biotechnologies
CinRx Pharma LLC
ConSynance Therapeutics
Cosmo Pharmaceuticals NV
Dong-A ST Co
Enterome Bioscience SA
GlaxoSmithKline
ImmuneBiotech AB
Innovative Med Concepts LLC
Ironwood Pharmaceuticals
LTT Bio-Pharma Co
Napo Pharmaceuticals
Nobilis Therapeutics
Orphomed Inc
Outpost Medicine
Palo BioFarma SL
Pfizer Inc
RaQualia Pharma Inc
RedHill Biopharma
Scythian Biosciences Corp
Seldar Pharma Inc
SK Biopharmaceuticals
Sumitomo Dainippon Pharma
Synergy Pharmaceuticals
Synthetic Biologics Inc
Tillotts Pharma
- Velicept Therapeutics Inc
Vitality Biopharma
4 IRRITABLE BOWEL SYNDROME R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN IRRITABLE BOWEL SYNDROME PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 IRRITABLE BOWEL SYNDROME PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Irritable Bowel Syndrome Pipeline Snapshot
2.3 Irritable Bowel Syndrome Pipeline by Phase
2.4 Irritable Bowel Syndrome Pipeline by Company
2.5 Irritable Bowel Syndrome Pipeline by Mechanism of Action
3 IRRITABLE BOWEL SYNDROME- COMPANY WISE PIPELINE ANALYSIS
4D Pharma PLC
Alfa Wassermann SpA
Allergan
Aptevo Therapeutics Inc
Ardelyx Inc
Assembly Biosciences
Astellas Pharma Inc
Axim Biotechnologies
CinRx Pharma LLC
ConSynance Therapeutics
Cosmo Pharmaceuticals NV
Dong-A ST Co
Enterome Bioscience SA
GlaxoSmithKline
ImmuneBiotech AB
Innovative Med Concepts LLC
Ironwood Pharmaceuticals
LTT Bio-Pharma Co
Napo Pharmaceuticals
Nobilis Therapeutics
Orphomed Inc
Outpost Medicine
Palo BioFarma SL
Pfizer Inc
RaQualia Pharma Inc
RedHill Biopharma
Scythian Biosciences Corp
Seldar Pharma Inc
SK Biopharmaceuticals
Sumitomo Dainippon Pharma
Synergy Pharmaceuticals
Synthetic Biologics Inc
Tillotts Pharma
- Velicept Therapeutics Inc
Vitality Biopharma
4 IRRITABLE BOWEL SYNDROME R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN IRRITABLE BOWEL SYNDROME PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Irritable Bowel Syndrome Pipeline by Phase, H1- 2018
Figure 2: Irritable Bowel Syndrome Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Irritable Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Irritable Bowel Syndrome Pipeline by Phase, H1- 2018
Figure 2: Irritable Bowel Syndrome Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Irritable Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Irritable Bowel Syndrome Pipeline by Phase, H1- 2018
Table 2: Irritable Bowel Syndrome Pipeline by Companies, H1- 2018
Table 3: Irritable Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
Table 4: 4D Pharma PLC Irritable Bowel Syndrome pipeline, May 2018
Table 5: Alfa Wassermann SpA Irritable Bowel Syndrome pipeline, May 2018
Table 6: Allergan Irritable Bowel Syndrome pipeline, May 2018
Table 7: Aptevo Therapeutics Inc Irritable Bowel Syndrome pipeline, May 2018
Table 8: Ardelyx Inc Irritable Bowel Syndrome pipeline, May 2018
Table 9: Assembly Biosciences Irritable Bowel Syndrome pipeline, May 2018
Table 10: Astellas Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
Table 11: Axim Biotechnologies Irritable Bowel Syndrome pipeline, May 2018
Table 12: CinRx Pharma LLC Irritable Bowel Syndrome pipeline, May 2018
Table 13: ConSynance Therapeutics Irritable Bowel Syndrome pipeline, May 2018
Table 14: Cosmo Pharmaceuticals NV Irritable Bowel Syndrome pipeline, May 2018
Table 15: Dong-A ST Co Irritable Bowel Syndrome pipeline, May 2018
Table 16: Enterome Bioscience SA Irritable Bowel Syndrome pipeline, May 2018
Table 17: GlaxoSmithKline Irritable Bowel Syndrome pipeline, May 2018
Table 18: ImmuneBiotech AB Irritable Bowel Syndrome pipeline, May 2018
Table 19: Innovative Med Concepts LLC Irritable Bowel Syndrome pipeline, May 2018
Table 20: Ironwood Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 21: LTT Bio-Pharma Co Irritable Bowel Syndrome pipeline, May 2018
Table 22: Napo Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 23: Nobilis Therapeutics Irritable Bowel Syndrome pipeline, May 2018
Table 24: Orphomed Inc Irritable Bowel Syndrome pipeline, May 2018
Table 25: Outpost Medicine Irritable Bowel Syndrome pipeline, May 2018
Table 26: Palo BioFarma SL Irritable Bowel Syndrome pipeline, May 2018
Table 27: Pfizer Inc Irritable Bowel Syndrome pipeline, May 2018
Table 28: RaQualia Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
Table 29: RedHill Biopharma Irritable Bowel Syndrome pipeline, May 2018
Table 30: Scythian Biosciences Corp Irritable Bowel Syndrome pipeline, May 2018
Table 31: Seldar Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
Table 32: SK Biopharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 33: Sumitomo Dainippon Pharma Irritable Bowel Syndrome pipeline, May 2018
Table 34: Synergy Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 35: Synthetic Biologics Inc Irritable Bowel Syndrome pipeline, May 2018
Table 36: Tillotts Pharma Irritable Bowel Syndrome pipeline, May 2018
Table 37: Velicept Therapeutics Inc Irritable Bowel Syndrome pipeline, May 2018
Table 38: Vitality Biopharma Irritable Bowel Syndrome pipeline, May 2018
Table 1: Irritable Bowel Syndrome Pipeline by Phase, H1- 2018
Table 2: Irritable Bowel Syndrome Pipeline by Companies, H1- 2018
Table 3: Irritable Bowel Syndrome Pipeline by Mechanism of Action, H1- 2018
Table 4: 4D Pharma PLC Irritable Bowel Syndrome pipeline, May 2018
Table 5: Alfa Wassermann SpA Irritable Bowel Syndrome pipeline, May 2018
Table 6: Allergan Irritable Bowel Syndrome pipeline, May 2018
Table 7: Aptevo Therapeutics Inc Irritable Bowel Syndrome pipeline, May 2018
Table 8: Ardelyx Inc Irritable Bowel Syndrome pipeline, May 2018
Table 9: Assembly Biosciences Irritable Bowel Syndrome pipeline, May 2018
Table 10: Astellas Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
Table 11: Axim Biotechnologies Irritable Bowel Syndrome pipeline, May 2018
Table 12: CinRx Pharma LLC Irritable Bowel Syndrome pipeline, May 2018
Table 13: ConSynance Therapeutics Irritable Bowel Syndrome pipeline, May 2018
Table 14: Cosmo Pharmaceuticals NV Irritable Bowel Syndrome pipeline, May 2018
Table 15: Dong-A ST Co Irritable Bowel Syndrome pipeline, May 2018
Table 16: Enterome Bioscience SA Irritable Bowel Syndrome pipeline, May 2018
Table 17: GlaxoSmithKline Irritable Bowel Syndrome pipeline, May 2018
Table 18: ImmuneBiotech AB Irritable Bowel Syndrome pipeline, May 2018
Table 19: Innovative Med Concepts LLC Irritable Bowel Syndrome pipeline, May 2018
Table 20: Ironwood Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 21: LTT Bio-Pharma Co Irritable Bowel Syndrome pipeline, May 2018
Table 22: Napo Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 23: Nobilis Therapeutics Irritable Bowel Syndrome pipeline, May 2018
Table 24: Orphomed Inc Irritable Bowel Syndrome pipeline, May 2018
Table 25: Outpost Medicine Irritable Bowel Syndrome pipeline, May 2018
Table 26: Palo BioFarma SL Irritable Bowel Syndrome pipeline, May 2018
Table 27: Pfizer Inc Irritable Bowel Syndrome pipeline, May 2018
Table 28: RaQualia Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
Table 29: RedHill Biopharma Irritable Bowel Syndrome pipeline, May 2018
Table 30: Scythian Biosciences Corp Irritable Bowel Syndrome pipeline, May 2018
Table 31: Seldar Pharma Inc Irritable Bowel Syndrome pipeline, May 2018
Table 32: SK Biopharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 33: Sumitomo Dainippon Pharma Irritable Bowel Syndrome pipeline, May 2018
Table 34: Synergy Pharmaceuticals Irritable Bowel Syndrome pipeline, May 2018
Table 35: Synthetic Biologics Inc Irritable Bowel Syndrome pipeline, May 2018
Table 36: Tillotts Pharma Irritable Bowel Syndrome pipeline, May 2018
Table 37: Velicept Therapeutics Inc Irritable Bowel Syndrome pipeline, May 2018
Table 38: Vitality Biopharma Irritable Bowel Syndrome pipeline, May 2018
